Relacionar Columnas Diabetes Oral MedsVersión en línea NUr115 Oral Diabetic Agents por Concetta Fiorentino 1 Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels. 2 Sensitize body tissue to insulin: stimulates insulin receptor sites. 3 Usually given once a day. 4 Enhances glucose-dependent insulin secretion. 5 Prevents kidneys from reabsorbing glucose. 6 Stimulate beta cells of the pancreas. 7 Inhibit production of glucose by the liver. 8 Stimulate pancreas to secrete insulin. 9 Drug to drug interaction with NSAIDS. 10 Do not increased insulin secretion. 11 Possible side-effect of impaired platelet function. Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance glipizide Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity) Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia) Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl) Januvia Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus) Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix) Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance) Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset) Avandia
Crear